esophageal cancer
Conditions
Interventions
Experimental group:On the basis of the control group, an additional 20mL of Compound Kushen Injection was administered, diluted with 250mL of 0.9% sodium chloride solution, and infused intravenously o
patients were treated for one course.
Control group:Nedaplatin 80mg/m2 was dissolved in 500mL of 0.9% sodium chloride solution for intravenous infusion on day 1
Docetaxel 75mg/m2 was dissolved in 500mL of 0.9% sodium chloride solution for intravenous infusion on day 1
Camrelizumab for injection, 200mg per dose, was administered via intravenous infusion on day 1. A 21-day period constituted one course of treatment. Patients were treated for one course.
Sponsors
Yecheng County People's Hospital, Kashgar, Xinjiang
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? Patients with clinically diagnosed advanced esophageal cancer through pathology. ? Newly diagnosed patients who are either not eligible for surgery or refuse surgery. ? Patients with at least one measurable lesion that can be evaluated according to the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). ? Patients with complete clinical data and follow-up records. ? Patients with basically normal organ function. ? Patients aged between 18 and 75 years. ? Patients with an expected survival period of =6 months. ? Patients who voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: ? Patients who have received any therapeutic drugs or equivalent traditional Chinese medicines within 2 weeks. ? Patients with severe autoimmune diseases. ? Patients with serious, uncontrolled organic diseases or infections, such as decompensated heart, lung, liver, or kidney failure. ? Patients with severe heart, lung, liver, or kidney damage; patients with a severe allergy history. ? Patients who are unable to eat or have cachexia. ? Patients who are allergic to the drugs used in this trial. ? Patients with a history of severe psychological or psychiatric disorders, drug addiction, or alcohol dependency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy;Adverse event; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Tumor markers;T lymphocyte subsets; | — |
Countries
China
Contacts
Public ContactLi Heng
Thoracic Surgery Department, Yecheng County People's Hospital, Kashgar, Xinjiang
Outcome results
None listed